Transcriptomic analysis of HDAC6-selective and broad HDAC inhibitors in human WT iPSC cardiomyocytes
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA747263 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR15175800.fastq.gz | Fastqsanger.gz | |||
| SRR15175801.fastq.gz | Fastqsanger.gz | |||
| SRR15175802.fastq.gz | Fastqsanger.gz | |||
| SRR15175803.fastq.gz | Fastqsanger.gz | |||
| SRR15175804.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 63 |
Similar Datasets
Project description:Dilated cardiomyopathy (DCM) is characterized by reduced cardiac output, as well as thinning and enlargement of left ventricular chambers. These characteristics eventually lead to heart failure. Current standards of care do not target the underlying molecular mechanisms associated with genetic forms of heart failure, driving a need to develop novel therapeutics for DCM. To identify candidate therapeutics, we developed an in vitro DCM model using induced pluripotent stem cell–derived cardiomyocytes (iPSC-CMs) deficient in BCL2-associated athanogene 3 (BAG3). With these BAG3-deficient iPSC-CMs, we identified cardioprotective drugs with a phenotypic screen and deep learning. Using a library of 5500 bioactive compounds and siRNA validation, we identified that inhibiting histone deacetylase 6 (HDAC6) was cardioprotective at the sarcomere level. We translated this finding to a BAG3 cardiac-knockout (BAG3cKO) mouse model of DCM, showing that inhibiting HDAC6 with two isoform-selective inhibitors (tubastatin A and a novel inhibitor TYA-018) protected heart function. In BAG3cKO and BAG3 E455K mice, HDAC6 inhibitors improved left ventricular ejection fraction and reduced left ventricular diameter at diastole and systole. We also found that HDAC6 inhibitors protected the microtubule network from mechanical damage, increased autophagic flux, decreased apoptosis, and reduced inflammation in the heart. Our results demonstrate the power of combining iPSC-CMs with phenotypic screening and deep learning to accelerate target and drug discovery, and they support the development of novel therapies that address underlying mechanisms associated with heart disease.
2021-12-31 | GSE180248 | GEO
Project description:Foxp3+ T-regulatory cells (Tregs) are key to immune homeostasis such that their diminished numbers or function can cause autoimmunity and allograft rejection. Foxp3+ Tregs express histone/protein deacetylases (HDACs) that regulate chromatin remodeling, gene expression and protein function. Pan-HDAC inhibitors developed for oncology enhance Treg production and suppression but have limited non-oncologic applications given their broad effects. We show, using HDAC6-deficient mice and WT mice treated with HDAC6-specific inhibitors, that HDAC6 inhibition promotes Treg suppressive activity in models of inflammation and autoimmunity, including multiple forms of experimental colitis and fully MHC-incompatible cardiac allograft rejection. Many of the beneficial effects of HDAC6 targeting are also achieved by inhibition of the HDAC6-regulated protein, HSP90. Hence, selective targeting of a single HDAC isoform, HDAC6, or its downstream target, HSP90, can promote Treg-dependent suppression of autoimmunity and transplant rejection. RNA from three independent samples from magnetically separated CD4+CD25+ Treg of HDAC6 knock out, compared to wild type (C57BL6) control
2011-05-01 | E-GEOD-27896 | biostudies-arrayexpress
Project description:Foxp3+ T-regulatory cells (Tregs) are key to immune homeostasis such that their diminished numbers or function can cause autoimmunity and allograft rejection. Foxp3+ Tregs express histone/protein deacetylases (HDACs) that regulate chromatin remodeling, gene expression and protein function. Pan-HDAC inhibitors developed for oncology enhance Treg production and suppression but have limited non-oncologic applications given their broad effects. We show, using HDAC6-deficient mice and WT mice treated with HDAC6-specific inhibitors, that HDAC6 inhibition promotes Treg suppressive activity in models of inflammation and autoimmunity, including multiple forms of experimental colitis and fully MHC-incompatible cardiac allograft rejection. Many of the beneficial effects of HDAC6 targeting are also achieved by inhibition of the HDAC6-regulated protein, HSP90. Hence, selective targeting of a single HDAC isoform, HDAC6, or its downstream target, HSP90, can promote Treg-dependent suppression of autoimmunity and transplant rejection.
2011-05-01 | GSE27896 | GEO
Project description:Expression profiling of neonatl rat ventricular cardiomyocytes (NRVMs) upon the treatement of Class IIa HDAC inhibitor
2019-04-23 | GSE130150 | GEO
Project description:Although bladder-preserving trimodality therapy is recognized for patients with muscle-invasive bladder cancer (MIBC), chemotherapy can have toxic effects. Inhibitors to histone deacetylases (HDACis) have been identified as an effective strategy to enhance the radiotherapy (RT) effect, and several of them have clinical efficacy in BC. However, little is known about how a specific HDAC6 inhibitor (HDAC6i) acts in concert with RT. Knockdown of HDAC6 enhanced the radiosensitization of BC cells and increased γH2AX accumulation, similar to the effect of panobinostat, a pan-HDACi. Applying tubacin, a selective HDAC6i, to T24 cells induced H3K9ac and α-tubulin acetylation, and significantly decreased clonogenic cell survival when combined with RT. Further transcriptomic analysis of shHDAC6-transduced T24 cells under irradiation showed that genes that were highly downregulated compared to the levels in response to RT alone were significantly enriched in the inflammatory response. Moreover, HDAC6 knockdown counteracted the RT-induced mRNA expression of CXCL1, SERPINE1, SDC1 and SDC2. Importantly, tubacin suppressed RT-promoted invaded/migrated T24 cells, whereas panobinostat elevated RT-induced CXCL1 expression and invasion/migration abilities. This phenotype was significantly abrogated by the CXCL1 antibody, indicating that RT-induced CXCL1 is the key regulator contributing to BC malignancy. Immunohistochemical evaluation of tumours from BC patients supported the correlation between CXCL1 overexpression and poor prognosis. Unlike the pan-HDACi, the selective HDAC6i tubacin can enhance BC radiosensitization and suppress RT-induced oncogenic CXCL1-Snail signalling, thus further advancing the therapeutic potential of tubacin with RT.
2023-04-07 | GSE197659 | GEO
Project description:Despite the anticancer activity of pan-histone deacetylase (HDAC) inhibitors, their clinical use has been limited due to toxicity. However, the development of more specific inhibitors that selectively inhibit individual HDACs is emerging as a novel and well-tolerated alternative. Here, we present the results of the first clinical trial evaluating the activity of ricolinostat (the leading HDAC6 inhibitor) in breast cancer (BC) patients. We have developed a computational network-based algorithm to evaluate the activity of the HDAC6 protein, based on the enrichment of its transcriptional targets in differentially expressed genes (HDAC6 score). Through preclinical in vitro and in vivo studies, we confirmed that the HDAC6 score can stratify the sensitivity of BC cells to ricolinostat treatment and may thus have value as a predictive biomarker. Moreover, analysis of ~3,000 primary human breast cancers showed that ~30% of them present high HDAC6 scores. Based on these results, we designed a phase Ib clinical trial to evaluate the activity of ricolinostat plus nab-paclitaxel in metastatic BC patients. Study results showed that the two agents can be safely combined, that clinical activity is identified specifically in patients with HR+/HER2- disease, and that the HDAC6 score was predictive of response. Expansion of our analysis to other tumor types identified multiple cohorts enriched in high HDAC6 score samples. These results suggest that the HDAC6 score may provide an effective predictive biomarker of ricolinostat sensitivity in multiple human cancers.
2023-02-09 | GSE180606 | GEO
Project description:Histone deacetylase 6 (HDAC6) is overexpressed in multiple myeloma (MM) patients and may be involved in the acquisition of resistance to conventional treatments. Here, we propose a two-residue mutation impairing the HDAC6 ZnF-UBP domain. HDAC6 knockout and ZnF-UBP mutant RPMI 8226 MM cell lines were generated using CRISPR-Cas9. MM cells harboring this mutation showed impaired aggresome formation, cell growth and a dysregulated gene expression profile in a more pronounced manner than the HDAC6 knockout cells.
2024-04-08 | GSE263138 | GEO
Project description:Despite the anticancer activity of pan-histone deacetylase (HDAC) inhibitors, their clinical use has been limited due to toxicity. However, the development of more specific inhibitors that selectively inhibit individual HDACs is emerging as a novel and well-tolerated alternative. Here, we present the results of the first clinical trial evaluating the activity of ricolinostat (the leading HDAC6 inhibitor) in breast cancer (BC) patients. We have developed a computational network-based algorithm to evaluate the activity of the HDAC6 protein, based on the enrichment of its transcriptional targets in differentially expressed genes (HDAC6 score). Through preclinical in vitro and in vivo studies, we confirmed that the HDAC6 score can stratify the sensitivity of BC cells to ricolinostat treatment and may thus have value as a predictive biomarker. Moreover, analysis of ~3,000 primary human breast cancers showed that ~30% of them present high HDAC6 scores. Based on these results, we designed a phase Ib clinical trial to evaluate the activity of ricolinostat plus nab-paclitaxel in metastatic BC patients. Study results showed that the two agents can be safely combined, that clinical activity is identified specifically in patients with HR+/HER2- disease, and that the HDAC6 score was predictive of response. Expansion of our analysis to other tumor types identified multiple cohorts enriched in high HDAC6 score samples. These results suggest that the HDAC6 score may provide an effective predictive biomarker of ricolinostat sensitivity in multiple human cancers.
2021-04-14 | GSE148623 | GEO
Project description:Targeting histone/protein deacetylase (HDAC)-6, -9, or Sirtuin-1 (Sirt1) augments the suppressive functions of Foxp3+ T regulatory (Treg) cells, but it is unclear if this involves different mechanisms, such that combined inhibition would be beneficial. We compared the suppressive functions of Tregs from wild-type C57BL/6 mice or mice with global (HDAC6-/-, HDAC9-/-, dual HDAC6/9-/-) or conditional deletion (CD4-Cre or Foxp3-Cre and floxed Sirt1; GSE26425) alone, or after treatment with isoform-selective HDAC inhibitors (HDACi). We found the heat shock response was crucial in mediating the effects of HDAC6, but not Sirt1 inhibition. Furthermore, while HDAC6, HDAC9 and Sirt1 all deacetylate Foxp3, each has diverse effects on Foxp3 transcription, and loss of HDAC9 is associated with stabilization of Stat5 acetylation and its transcriptional activity. Targeting different HDAC can increase Treg function by multiple and additive mechanisms, indicating the therapeutic potential for combinations of HDACi in the management of autoimmunity and alloresponses post-transplant. RNA from three independent samples of magnetically separated CD4+CD25+ Treg of HDAC9-/- mice, compared to wild type (C57BL/6) control.
2012-06-20 | E-GEOD-36095 | biostudies-arrayexpress
Project description:The accumulation of β-amyloid (Aβ) and hyperphosphorylated tau, along with neuroinflammation, are key drivers of Alzheimer’s disease (AD) pathology. Here, we identify ramalin, a natural antioxidant, as a promising therapeutic agent that targets multiple pathological mechanisms in AD models. Ramalin reduces BACE1 protein levels, without affecting its transcription, translation, or proteolytic activity. This reduction is mediated through selective inhibition of histone deacetylase 6 (HDAC6), as confirmed by genome-wide drug target screening and HDAC activity assays. Knockdown of HDAC6 resulted in decreases in BACE1 levels, positioning HDAC6 as a mediator of BACE1 regulation. Ramalin exhibits anti-inflammatory effects by downregulating iNOS and the NLRP3 inflammasome. In AD mouse models, ramalin treatment significantly reduced neuroinflammation, Aβ plaque burden, tau hyperphosphorylation and improved cognitive performance. Notably, ramalin reversed Aβ oligomer-induced synaptic transmission impairment and restored synaptic vesicle recycling in hippocampal neurons. Transcriptomic analysis revealed ramalin modulates MAPK signaling pathway, reducing phosphorylation of JNK and ERK, which are implicated in tau pathology. These findings position ramalin as a multi-target therapeutic agent, offering neuroprotection through coordinated modulation of BACE1, tau phosphorylation, and inflammatory pathways. Given these promising results, ramalin represents a potential breakthrough for the treatment of AD by targeting key pathogenic processes at multiple levels.
2026-01-13 | GSE304876 | GEO